Navigation Links
Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting

TAMPA, Fla., April 23, 2007 /PRNewswire/ -- Sirion Therapeutics announced today that data on two of the Company's pipeline compounds, ST-601 (difluprednate) and ST-602 (fenretinide), will be presented at the 2007 annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL. In addition to these presentations, the company will be hosting a reception for ARVO attendees.

ST-601 (difluprednate) is currently being evaluated in two phase III clinical trials in the treatment of ocular inflammation following cataract surgery. ST-601 (difluprednate) was acquired by Sirion last year through an exclusive licensing agreement with Senju Pharmaceutical Co., LTD of Japan. The agreement gives Sirion the U.S. rights to develop and market a topical ophthalmic emulsion containing the steroid compound difluprednate for the treatment of inflammatory eye diseases and conditions.

ST-602 (fenretinide) is currently being evaluated in a phase II clinical trial in the treatment of Geographic Atrophy (GA) in patients with age-related macular degeneration. The trial is a multicenter, randomized, double-masked, placebo controlled, dose-comparison in up to 225 patients in approximately 20 sites in the United States.

"We are pleased to announce the upcoming schedule of presentations relating to difluprednate and fenretinide at the ARVO annual conference. ARVO is the one of the oldest, largest and most highly respected vision research organizations in the world," stated Barry Butler, President and Chief Executive Officer of Sirion Therapeutics. "This is exciting news for our company in that it is the first time we will be presenting scientific data on our pipeline compounds. These presentations will provide support of the potential future clinical utility of these compounds in the treatment of ophthalmic eye diseases and conditions and demonstrate our commitment to discovering, de
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:8/29/2014)... 2014 According to a ... Extraction type (SFE, Cold Pressed, Organic Solvent, & Others), ... Food Supplements, Fragrance, & Others) - Global Trends & ... segments the Amaranth Seed Oil Market with an ... terms of value. The Amaranth Seed Oil Market ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Md., April 11, 2012 Sunpeaks Ventures, Inc. (OTCBB: ... its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") ... an agreement with DS Healthcare Limited to assist in ... Under terms of the agreement, DS Healthcare will evaluate ...
... has used an electronic clinical system since its inception in ... original technology with an enterprise clinical and financial solution from ... start out as a completely electronic hospital. But we realize ... all of our needs," says Jeremy Lyman, CFO at the ...
Cached Medicine Technology:Sunpeaks Ventures Enters Agreement with UK Based Healthcare Firm to Introduce Clotamin to UK and European Union Countries 2Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 2Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 3
(Date:9/1/2014)... (PRWEB) September 01, 2014 Registration is now ... Warriors® 5K and 1-Mile Race to be held on Sunday, ... Plaza Court Yard at Harmon Meadow in Secaucus, New Jersey. ... Warriors®, a national nonprofit dedicated to restoring a sense of ... service members and our military families. , General registration is ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... US FDA announced on August 28, that specific lots ... (Class I) as the device may reverse directions ... Synthes Craniomaxillofacial (CMF) Distraction System is an implant used ...
(Date:9/1/2014)... US (PRWEB) September 01, 2014 ... view into Heartbeat Experts’ perspectives on ... market. , Download the flash report to ... for any launching Diabetes product:, ... within an increasingly crowded market , ...
(Date:8/31/2014)... Just in time for Washington’s Indian Summer, ... Alaska Salmon, award winning chowder and legendary sourdough ... Lake location , Sunday, September 28, 2014 from 1 pm ... salmon BBQ culinary delights. Live music will add to the ... Rico and Mexico will be featured. “There is no ...
(Date:8/31/2014)... to celebrate the coming of autumn, Guangdong FODAY Automobile ... big promotion. Now, all the global clients can access cheap, ... are made with great materials. FODAY Automobile strives to offer ... of fact, it is providing big discounts on many of ... cheap cars can visit its website for more details. ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Diabetes Products 2Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2
... SMITHFIELD, R.I., July 29 FGX International,(Nasdaq: FGXI ... sunglasses and costume jewelry, today announced financial results,for its ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071025/NETH104LOGO ), ... sales increased 14% to $71.6 million in the current ...
... WHITE PLAINS, N.Y., July 29 Four leaders,from the ... been elected to the national Board of Trustees of ... March of Dimes trustees, who serve as volunteers, represent ... and serve five-year,terms., The new trustees are:, ...
... cancer screening program in Norway and an approach to ... are equally sensitive for detecting cancer, researchers report in ... of the National Cancer Institute . But the recall ... Breast cancer screening in the United States is usually ...
... Income Per Share, SAN JOSE, Calif., July 29 ... leading provider of medical devices,for the minimally invasive treatment ... second quarter ended June 30, 2008., Net revenues ... $31.9,million compared with $17.2 million for the second quarter ...
... (Pink,Sheets: VSMD) announced today that Craig M. Walker, M.D., ... the number of directors from,four to five. Dr. Walker ... cardiologist, clinical investigator and thought leader., "Dr. Walker ... one of the,world,s leading experts in the care of ...
... literacy and,curbing HIV/AIDS is the centerpiece of the U.S. ... stabilize parts of,Haiti plagued by community unrest., The ... -- will,target public and private primary schools as well ... who manages a worldwide education and,health program for USAID., ...
Cached Medicine News:Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 2Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 3Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 4Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 5Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 6Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 7Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 8Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 9Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 10Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 11Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 12Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 13Health News:FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008 14Health News:Four Named to March of Dimes Board of Trustees 2Health News:Four Named to March of Dimes Board of Trustees 3Health News:Four Named to March of Dimes Board of Trustees 4Health News:Four Named to March of Dimes Board of Trustees 5Health News:Four Named to March of Dimes Board of Trustees 6Health News:Four Named to March of Dimes Board of Trustees 7Health News:2 different breast cancer screening strategies are equally effective 2Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 2Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 3Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 4Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 5Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 6Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 7Health News:VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales 8Health News:VASAMED(R) Appoints Craig M. Walker, MD to Board of Directors 2Health News:Three Rs and HIV/AIDS Mark New Haiti Literacy Plan 2